ArticleFrontiers in cardiovascular medicine2026
Prognostic significance of pan-immune-inflammatory value in adverse cardiovascular and cerebrovascular events post-percutaneous coronary intervention in diabetic patients with coronary heart disease.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pan-immune-inflammation value (PIV) is a novel biomarker reflecting systemic inflammation. Its role in predicting adverse cardiovascular and cerebrovascular events in diabetic patients after percutaneous coronary intervention (PCI) is unclear. Objectives: This study evaluated PIV's prognostic value for major adverse cardiovascular and cerebrovascular events (MACCE) post-PCI in diabetics with coronary heart disease (CHD), and compared it to other inflammation-based markers like systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR). Methods: Retrospective analysis of diabetic CHD patients undergoing PCI. PIV was calculated as (neutrophil × platelet × monocyte)/lymphocyte counts from pre-procedural blood. Optimal cutoff determined via ROC curve. Patients stratified into high/low PIV groups. Follow-up for MACCE (e.g., MI, stroke, revascularization). Kaplan-Meier (KM) survival, Cox regression, and ROC comparisons assessed outcomes. Results: Over 24-month median follow-up, 52 MACCE occurred (24.8%). High-PIV group had higher incidence (37.7% vs. 11.5%, Conclusions: PIV is a robust, independent predictor of MACCE post-PCI in diabetics, with superior accuracy over other markers. It offers cost-effective risk stratification. Limitations: retrospective design; prospective validation needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.